Mao-Lin Yan

机构：Fujian Medical University, Fujian Provincial Hospital · ORCID：0009-0003-5188-6796

发表论文 38 篇 · 总被引 416 次 · h-index 10

代表论文

• Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial (2024 · Nature Medicine · 被引 130)
• Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study (2023 · International Journal of Surgery · 被引 61)
• Short-term and long-term outcomes after robotic versus open hepatectomy in patients with large hepatocellular carcinoma: a multicenter study (2023 · International Journal of Surgery · 被引 21)
• Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0–A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis (2022 · Hepatology International · 被引 21)
• Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition) (2024 · BioScience Trends · 被引 20)
• Identification and expression analysis of CCCH gene family and screening of key low temperature stress response gene CbuC3H24 and CbuC3H58 in Catalpa bungei (2024 · BMC Genomics · 被引 12)